Autopsy report · NCT03335059

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.

“poor enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months before it started.
• Ran for about 11 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Medical Enterprises Ltd.

Sponsor type

Industry

Conditions

Bladder Cancer; Bladder Neoplasm; Bladder Tumors; Cancer of Bladder; Cancer of the Bladder; Malignant Tumor of Urinary Bladder

Interventions

Synergo® RITE + MMC

Participants

5

Sites

4

Countries

United States

Trials that died the same way

• Use of Prokinetics in Early Enteral Feeding in Preterm Infants
  “very poor enrollment” (96% match in meaning)
• Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC
  “Inadequate enrollment” (91% match in meaning)
• Effect of Holofiber Socks and Bedding on Pain and Quality of Sleep in Subjects With Chronic Foot Pain
  “Low enrollment” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.